Lucy Coutts

Lucy Coutts is an investment director at JM Finn and a shareholder in AstraZeneca. She has expressed skepticism regarding the potential merger between AstraZeneca and Bristol Myers Squibb, suggesting that the only notable advantage for AstraZeneca would be to enhance its U.S. market presence, while indicating that such a deal would likely be more beneficial for Bristol Myers shareholders.